| 2026 |
Carlino, M. S., Gao, B., Michael, M., Marshall, H., Gunjur, A., Chan, H., . . . Klein, O. (2026). Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial. JAMA Oncology, 9 pages.
DOI Scopus1 WoS1 |
| 2025 |
Thavaneswaran, S., Lin, F., Espinoza, D., Grady, J., Kok, P. S., Chinchen, S., . . . Thomas, D. (2025). A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden. Npj Precision Oncology, 9(1).
DOI |
| 2025 |
Liapis, V., Wittwer, N. L., Tieu, W., Gargett, T., Brown, M. P., & Staudacher, A. H. (2025). Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®. Journal of Translational Medicine, 23(1, article no. 651), 651-1-651-18.
DOI Scopus1 WoS1 Europe PMC1 |
| 2025 |
Thavaneswaran, S., Sim, H. W., Grady, J., Espinoza, D., Huang, M. L., Lin, F., . . . Thomas, D. (2025). A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling. Oncologist, 30(8), oyae339.
DOI |
| 2025 |
Satheakeerthy, S., Beecher, M., Booth, A. E. C., Stretton, B., Kovoor, J., Gupta, A., . . . Bacchi, S. (2025). Automating cancer registries: Pearls and pitfalls. Health Information Management Journal, 10 pages.
DOI |
| 2025 |
Long, G. V., Atkinson, V., Lo, S. N., Guminski, A. D., Sandhu, S. K., Brown, M. P., . . . Menzies, A. M. (2025). Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 26(3), 320-330.
DOI Scopus13 WoS15 Europe PMC12 |
| 2024 |
Thavaneswaran, S., Lin, F., Grady, J. P., Espinoza, D., Huang, M. L., Chinchen, S., . . . Thomas, D. M. (2024). A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation. Npj Precision Oncology, 8(1).
DOI Scopus4 |
| 2024 |
Brown, M. P. (2024). CAR spacers: not just filling space. Molecular therapy : the journal of the American Society of Gene Therapy, 32(10), 3207-3208.
DOI |
| 2024 |
Cohen, G., Rapoport, B., Chan, S. W., Ruff, P., Arance, A., Eizmendi, K. M., . . . Jacobs, C. (2024). Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. Plos One, 19(11 November), e0309778.
DOI Scopus2 Europe PMC2 |
| 2024 |
Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659-1-e008659-17.
DOI Scopus33 WoS31 Europe PMC26 |
| 2024 |
Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
DOI Scopus10 WoS11 Europe PMC7 |
| 2023 |
Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., . . . Long, G. V. (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41(3), 517-527.
DOI Scopus127 WoS119 Europe PMC113 |
| 2023 |
Lemech, C., Dredge, K., Bampton, D., Hammond, E., Clouston, A., Waterhouse, N. J., . . . Goldstein, D. (2023). Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. Journal for immunotherapy of cancer, 11(1), 1-12.
DOI Scopus26 WoS25 Europe PMC25 |
| 2023 |
Wittwer, N. L., Staudacher, A. H., Liapis, V., Cardarelli, P., Warren, H., & Brown, M. P. (2023). An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. Journal for ImmunoTherapy of Cancer, 11(3), e006274-1-e006274-16.
DOI Scopus23 WoS25 Europe PMC17 |
| 2023 |
Thompson, J. R., Lai-Kwon, J., Morton, R. L., Guminski, A. D., Gonzalez, M., Atkinson, V., . . . Bartula, I. (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.. Immunotherapy, 15(8), 593-610.
DOI Scopus3 WoS3 Europe PMC2 |
| 2023 |
Pickering, C., Aiyetan, P., Xu, G., Mitchell, A., Rice, R., Najjar, Y. G. G., . . . Boland, G. M. M. (2023). Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Frontiers In Immunology, 14(1187332), 1-14.
DOI Scopus8 WoS9 Europe PMC8 |
| 2023 |
Day, D., Park, J. J., Coward, J., Markman, B., Lemech, C., Kuo, J. C., . . . Tse, A. N. (2023). A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer. British Journal of Cancer, 129(10), 1608-1618.
DOI Scopus6 WoS4 Europe PMC3 |
| 2023 |
Gardam, B., Gargett, T., Brown, M. P., & Ebert, L. M. (2023). Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma. Frontiers in Immunology, 14, 1261257-1-1261257-14.
DOI Scopus12 WoS13 Europe PMC12 |
| 2023 |
Wittwer, N. L., Brown, M. P., Liapis, V., & Staudacher, A. H. (2023). Antibody drug conjugates: hitting the mark in pancreatic cancer?. Journal of Experimental and Clinical Cancer Research, 42(1, article no. 280), 280-1-280-16.
DOI Scopus24 WoS21 Europe PMC19 |
| 2023 |
Soon, J. A., To, Y. H., Alexander, M., Trapani, K., Brown, M. P., & IJzerman, M. (2023). A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy, 38(100441), 1-8.
DOI Scopus1 WoS1 |
| 2022 |
Staudacher, A. H., Li, Y., Liapis, V., & Brown, M. P. (2022). The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell lines. Cancer Reports, 5(8), e1543-1-e1543-11.
DOI Scopus6 WoS6 Europe PMC4 |
| 2022 |
Tan, L. Y., Cockshell, M. P., Moore, E., Myo Min, K. K., Ortiz, M., Johan, M. Z., . . . Bonder, C. S. (2022). Vasculogenic mimicry structures in melanoma support the recruitment of monocytes. OncoImmunology, 11(1), e2043673-1-e2043673-18.
DOI Scopus18 WoS19 Europe PMC19 |
| 2022 |
Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., . . . Gargett, T. (2022). Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in immunology, 13, 850226-1-850226-19.
DOI Scopus23 WoS21 Europe PMC18 |
| 2022 |
Nazarizadeh, A., Staudacher, A. H., Wittwer, N. L., Turnbull, T., Brown, M. P., & Kempson, I. (2022). Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives. International Journal of Molecular Sciences, 23(9), 4707-1-4707-15.
DOI Scopus36 WoS32 Europe PMC26 |
| 2022 |
Staudacher, A. H., Liapis, V., Wittwer, N. L., Tieu, W., Lam, H. C., Leusen, J., & Brown, M. P. (2022). Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®. Biomedicine and Pharmacotherapy, 151(article no. 113090), 113090-1-113090-10.
DOI WoS1 |
| 2022 |
Cilento, M. A., Kim, C., Chang, S., Farshid, G., & Brown, M. P. (2022). Three cases of BRAF-mutant melanoma with divergent differentiation masquerading as sarcoma.. Pathologica, 114(3), 217-220.
DOI Scopus7 WoS7 Europe PMC5 |
| 2022 |
Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
DOI Scopus79 WoS79 Europe PMC75 |
| 2021 |
Liapis, V., Tieu, W., Wittwer, N. L., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2021). Positron emission tomographic imaging of tumor cell death using zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models. Molecular Imaging and Biology, 23(6), 914-928.
DOI Scopus8 WoS9 Europe PMC6 |
| 2021 |
Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., & Bezak, E. (2021). Characteristic differences in radiation-induced DNA damage response in human papillomavirus-negative and human papillomavirus-positive head and neck cancers with accumulation of fractional radiation dose. Head and Neck, 43(10), 3086-3096.
DOI Scopus1 WoS1 Europe PMC1 |
| 2021 |
Brown, M. P., Ebert, L. M., & Gargett, T. (2021). Erratum: Clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma.. Clinical & translational immunology, 10(8), e1331.
DOI Scopus1 WoS1 Europe PMC1 |
| 2021 |
Liapis, V., Tieu, W., Wittwer, N. L., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2021). Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models (Molecular Imaging and Biology, (2021), 23, 6, (914-928), 10.1007/s11307-021-01620-1). Molecular Imaging and Biology, 23(6), 929.
DOI |
| 2021 |
Begley, C. G., Ashton, M., Baell, J., Bettess, M., Brown, M. P., Carter, B., . . . Sullivan, M. (2021). Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med, 13(612), 1-13.
DOI Scopus105 WoS88 Europe PMC84 |
| 2021 |
Salim, A., Tapia Rico, G., Shaikh, A., & Brown, M. P. (2021). A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies. Expert Opinion on Biological Therapy, 21(9), 1237-1251.
DOI Scopus6 WoS5 Europe PMC6 |
| 2021 |
Yeo, E. C. F., Brown, M. P., Gargett, T., & Ebert, L. M. (2021). The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cells, 10(3, article no. 607), 1-25.
DOI Scopus59 WoS54 Europe PMC48 |
| 2021 |
Oksdath Mansilla, M., Salazar-Hernandez, C., Perrin, S. L., Scheer, K. G., Cildir, G., Toubia, J., . . . Gomez, G. A. (2021). 3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC biomedical engineering, 3(6), 1-14.
DOI Europe PMC17 |
| 2021 |
Truong, N. T. H., Gargett, T., Brown, M. P., & Ebert, L. M. (2021). Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of car-t cell therapies. Cancers, 13(9, article no. 2225), 1-19.
DOI Scopus34 WoS31 Europe PMC25 |
| 2021 |
Eggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., . . . Ferrucci, P. F. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, 22(5), 643-654.
DOI Scopus333 Europe PMC256 |
| 2021 |
Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., . . . Schmidt, H. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, 22(5), 655-664.
DOI Scopus63 Europe PMC48 |
| 2021 |
Long, G. V., Robert, C., Butler, M. O., Couture, F., Carlino, M. S., O’Day, S., . . . Diab, A. (2021). Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clinical Cancer Research, 27(19), 5280-5288.
DOI Scopus31 Europe PMC29 |
| 2021 |
El Khawanky, N., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., . . . Zeiser, R. (2021). Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun, 12(1), 6436-1-6436-20.
DOI Scopus88 WoS83 Europe PMC79 |
| 2021 |
MacGregor, M., Safizadeh Shirazi, H., Chan, K. M., Ostrikov, K., McNicholas, K., Jay, A., . . . Vasilev, K. (2021). Cancer cell detection device for the diagnosis of bladder cancer from urine. Biosensors and Bioelectronics, 171(112699), 12 pages.
DOI Scopus38 WoS32 Europe PMC24 |
| 2020 |
Desai, J., Gan, H., Barrow, C., Jameson, M., Atkinson, V., Haydon, A., . . . Solomon, B. (2020). Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors. Journal of Clinical Oncology, 38(19), 2140-2150.
DOI Scopus95 Europe PMC77 |
| 2020 |
Foo, T., Tapia Rico, G., & Brown, M. P. (2020). Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma. BMJ Case Reports, 13(7), 4 pages.
DOI |
| 2020 |
Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., . . . Bezak, E. (2020). Intrinsic Radiosensitivity Is Not the Determining Factor in Treatment Response Differences between HPV Negative and HPV Positive Head and Neck Cancers.. Cells, 9(8), 1-14.
DOI Scopus7 WoS7 Europe PMC6 |
| 2020 |
Mislang, A., Mollard, R., Tapia Rico, G., Fairlie, W. D., Lee, E. F., Harris, T. J., . . . Brown, M. P. (2020). A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors. Cancer Chemotherapy and Pharmacology, 86(5), 589-594.
DOI Scopus4 WoS3 Europe PMC3 |
| 2020 |
Staudacher, A. H., Liapis, V., Tieu, W., Wittwer, N., & Brown, M. P. (2020). Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody. Journal of Controlled Release, 327, 779-787.
DOI Scopus9 WoS10 Europe PMC8 |
| 2020 |
Brown, M., Jersmann, H., Crowhurst, T., Van Vliet, C., Crouch, G., & Badiei, A. (2020). A challenging diagnosis of malignant mesothelioma with osteosarcomatous differentiation metastasizing to bone.. Respirol Case Rep, 8(8), e00664.
DOI Europe PMC1 |
| 2020 |
Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
DOI Scopus52 WoS48 Europe PMC47 |
| 2020 |
Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., & Bezak, E. (2020). Influence of the human papillomavirus on the radio-responsiveness of cancer stem cells in head and neck cancers. Scientific Reports, 10(1), 1-8.
DOI Scopus12 WoS13 Europe PMC10 |
| 2020 |
Liapis, V., Tieu, W., Rudd, S. E., Donnelly, P. S., Wittwer, N. L., Brown, M. P., & Staudacher, A. H. (2020). Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®. EJNMMI Radiopharmacy and Chemistry, 5(1), 27-1-27-15.
DOI Scopus11 WoS13 Europe PMC10 |
| 2020 |
Burdett, N., Hsu, K., Xiong, L., Tapia-Rico, G., Beckmann, K., Karapetis, C., & Brown, M. P. (2020). Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. Asia-Pacific Journal of Clinical Oncology, 16(2), 139-145.
DOI Scopus13 WoS12 Europe PMC10 |
| 2019 |
Staudacher, A. H., Li, Y., Liapis, V., Hou, J. J. C., Chin, D., Dolezal, O., . . . Brown, M. P. (2019). APOMAB antibody-drug conjugates targeting dead tumor cells are effective in vivo. Molecular Cancer Therapeutics, 18(2), 335-345.
DOI Scopus18 WoS18 Europe PMC16 |
| 2019 |
Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., . . . Blank, C. (2019). An open-label, multicentre safety study of vemurafenib in patients with BRAF <sup>V600</sup> -mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 107, 175-185.
DOI Scopus14 WoS13 Europe PMC12 |
| 2019 |
Zhang, P., Raju, J., Ullah, M. A., Au, R., Varelias, A., Gartlan, K. H., . . . Tey, S. K. (2019). Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic Tcells. Clinical Cancer Research, 25(6), 1749-1755.
DOI Scopus23 WoS22 Europe PMC19 |
| 2019 |
Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019). Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochemical Society Transactions, 47(2), 625-638.
DOI Scopus127 WoS121 Europe PMC108 |
| 2019 |
Gargett, T., TRUONG, N., EBERT, L., YU, W., & BROWN, M. (2019). Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 21(6), 593-602.
DOI Scopus32 WoS32 Europe PMC35 |
| 2019 |
Brown, M. P., Ebert, L. M., & Gargett, T. (2019). Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and translational immunology, 8(5, article no. e1050), 1-20.
DOI Scopus38 WoS36 Europe PMC33 |
| 2019 |
Mencel, J., Gargett, T., Karanth, N., Pokorny, A., Brown, M. P., & Charakidis, M. (2019). Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma. Asia-Pacific journal of clinical oncology, 15(6), 383-386.
DOI Scopus4 WoS3 Europe PMC4 |
| 2019 |
Gomez, G. A., Oksdath, M., Brown, M. P., & Ebert, L. M. (2019). New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology. Translational Cancer Research, 8(Suppl. 6), S606-S611.
DOI Scopus10 WoS10 Europe PMC12 |
| 2019 |
Jahan, S., Lea-Henry, T., Brown, M., & Karpe, K. (2019). An Unusual Case of Acute Phosphate Nephropathy. Kidney International Reports, 4(7), 1023-1026.
DOI Scopus3 |
| 2018 |
Staudacher, A. H., Liapis, V., & Brown, M. P. (2018). Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates. Antibody Therapeutics, 1(2), 55-63.
DOI Scopus21 |
| 2018 |
Gibbs, P., Heinemann, V., Sharma, N. K., Taieb, J., Ricke, J., Peeters, M., . . . Gordon, M. (2018). Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer, 17(4), e617-e629.
DOI Scopus63 WoS54 Europe PMC42 |
| 2018 |
Brown, M. P., & Mislang, A. (2018). Cancer immunotherapy: at a new immune frontier. Cancer forum, 42(1), 3-16. |
| 2018 |
Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., . . . Rueda Dominguez, A. (2018). Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, 19(4), 510-520.
DOI Scopus192 Europe PMC142 |
| 2018 |
Takhar, H., Singhal, N., Mislang, A., Kumar, R., Kim, L., Selva-Nayagam, S., . . . Brown, M. (2018). Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 14(1), 91-100.
DOI Scopus8 WoS9 Europe PMC6 |
| 2018 |
Dredge, K., Brennan, T., Hammond, E., Lickliter, J., Lin, L., Bampton, D., . . . Millward, M. (2018). A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. British Journal of Cancer, 118(8), 1035-1041.
DOI Scopus79 WoS76 Europe PMC73 |
| 2018 |
Ebert, L. M., Yu, W., Gargett, T., & Brown, M. P. (2018). Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 46(2), 391-401.
DOI Scopus29 WoS29 Europe PMC23 |
| 2018 |
Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., . . . McArthur, G. A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672-681.
DOI Scopus850 WoS787 Europe PMC704 |
| 2018 |
Reid, P., Wilson, P., Li, Y., Marcu, L., Staudacher, A., Brown, M., & Bezak, E. (2018). Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay. Scientific Reports, 8(1), 7 pages.
DOI Scopus10 WoS9 Europe PMC5 |
| 2018 |
Gargett, T., Abbas, M., Rolan, P., Price, J., Gosling, K., Ferrante, A., . . . Brown, M. (2018). Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer Immunology, Immunotherapy, 67(9), 1461-1472.
DOI Scopus86 WoS73 Europe PMC63 |
| 2017 |
Blank, C., Larkin, J., Arance, A., Hauschild, A., Queirolo, P., Del Vecchio, M., . . . Brown, M. (2017). Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 79, 176-184.
DOI Scopus34 Europe PMC26 |
| 2017 |
Reid, P., Wilson, P., Li, Y., Marcu, L. G., Staudacher, A. H., Brown, M. P., & Bezak, E. (2017). In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status. PLoS ONE, 12(10), 16 pages.
DOI Scopus20 WoS18 Europe PMC17 |
| 2017 |
Staudacher, A. H., & Brown, M. P. (2017). Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?. British Journal of Cancer, 117(12), 1736-1742.
DOI Scopus418 WoS382 Europe PMC341 |
| 2017 |
Hughes, A. E., Clarson, J., Gargett, T., Yu, W., Brown, M. P., Lopez, A. F., . . . Yong, A. S. M. (2017). Comment on 'KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study'. Leukemia research, 55, 55-57.
DOI Scopus3 WoS3 Europe PMC2 |
| 2017 |
Brown, M. P., Hissaria, P., Hsieh, A. H., Kneebone, C., & Vallat, W. (2017). Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. Journal of Neuroimmunology, 305, 16-18.
DOI Scopus56 WoS55 Europe PMC44 |
| 2017 |
Tan, L. Y., Martini, C., Fridlender, Z. G., Bonder, C. S., Brown, M. P., & Ebert, L. M. (2017). Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. Clinical and Translational Immunology, 6(3), e134-1-e134-9.
DOI Scopus27 WoS28 Europe PMC25 |
| 2017 |
Tadesse, S., Zhu, G., Mekonnen, L. B., Lenjisa, J. L., Yu, M., Brown, M. P., & Wang, S. (2017). A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. Future Medicinal Chemistry, 9(13), 1495-1506.
DOI Scopus16 WoS16 Europe PMC11 |
| 2017 |
Takhar, H., Mislang, A. R., Singhal, N., & Brown, M. P. (2017). Feasibility and kinetics of CD34⁺ hematopoietic progenitor cell mobilization in response to a single administration of docetaxel chemotherapy and pegfilgrastim in a contemporary cohort of patients with metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 13(1), 79-86.
DOI Europe PMC1 |
| 2017 |
Hsieh, A. H. C., Faithfull, S., & Brown, M. P. (2017). Risk of cumulative toxicity after complete melanoma response with pembrolizumab. BMJ Case Reports, 2017, bcr2016218308.
DOI Scopus7 Europe PMC5 |
| 2016 |
Lakhanpal, R., Sestak, I., Shadbolt, B., Bennett, G. M., Brown, M., Phillips, T., . . . Rezo, A. (2016). IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. Breast, 29, 147-152.
DOI Scopus20 Europe PMC16 |
| 2016 |
Dienstmann, R., Lassen, U., Cebon, J., Desai, J., Brown, M. P., Evers, S., . . . Tabernero, J. (2016). First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors. Targeted Oncology, 11(2), 149-156.
DOI Scopus1 |
| 2016 |
Tan, L., Mintoff, C., Johan, M., Ebert, B., Fedele, C., Zhang, Y., . . . Ebert, L. (2016). Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget, 7(29), 46492-46508.
DOI Scopus46 WoS46 Europe PMC42 |
| 2016 |
Gargett, T., Yu, W., Dotti, G., Yvon, E., Christo, S., Hayball, J., . . . Brown, M. (2016). GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Molecular Therapy, 24(6), 1135-1149.
DOI Scopus319 WoS295 Europe PMC281 |
| 2016 |
Al Darwish, R., Staudacher, A. H., Li, Y., Brown, M. P., & Bezak, E. (2016). Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy. Medical Physics, 43(11), 6145-6153.
DOI Scopus10 WoS10 Europe PMC9 |
| 2016 |
Gargett, T., Christo, S. N., Hercus, T. R., Abbas, N., Singhal, N., Lopez, A. F., & Brown, M. P. (2016). GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro. CLINICAL & TRANSLATIONAL IMMUNOLOGY, 5(12), 12 pages.
DOI Scopus39 WoS32 Europe PMC28 |
| 2016 |
Hsieh, A. H. C., Ferman, M., Brown, M. P., & Andrews, J. M. (2016). Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Reports, 2016, bcr2016216641-1-bcr2016216641-4.
DOI Scopus50 Europe PMC40 |
| 2016 |
Beenen, E., Brown, M., Gananadha, S., & Mosse, C. (2016). Elastofibroma of the pylorus presenting as gastric outlet obstruction: a case report and review of literature. ANZ Journal of Surgery, 86(11), 946-947.
DOI Scopus5 Europe PMC3 |
| 2015 |
Takhar, H., Singhal, N., Gowda, R., Penniment, M., Takhar, P., & Brown, M. (2015). Phase i study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Anti-Cancer Drugs, 26(10), 1069-1077.
DOI Scopus24 WoS22 Europe PMC19 |
| 2015 |
Hersh, E., Del Vecchio, M., Brown, M., Kefford, R., Loquai, C., Testori, A., . . . Hauschild, A. (2015). A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Annals of Oncology, 26(11), 2267-2274.
DOI Scopus78 WoS66 Europe PMC63 |
| 2015 |
Menzies, A. M., Atkinson, V. G., Brown, M. P., Carlino, M. S., Cebon, J., Guminski, A., . . . Sandhu, S. (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
Scopus1 WoS2 |
| 2015 |
Brown, M. P., Bezak, E., & Allen, B. J. (2015). The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. MELANOMA MANAGEMENT, 2(4), 353-366.
DOI WoS2 Europe PMC1 |
| 2015 |
Gargett, T., Fraser, C., Dotti, G., Yvon, E., & Brown, M. (2015). BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro. Journal of Immunotherapy, 38(1), 12-23.
DOI Scopus34 WoS35 Europe PMC33 |
| 2015 |
Christo, S., Diener, K., Nordon, R., Brown, M., Griesser, H., Vasilev, K., . . . Hayball, J. (2015). Scrutinizing calcium flux oscillations in T lymphocytes to deduce the strength of stimulus. Scientific Reports, 5(article no. 7760), 7760-1-7760-8.
DOI Scopus26 WoS25 Europe PMC25 |
| 2015 |
Gargett, T., & Brown, M. (2015). Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy, 17(4), 487-495.
DOI Scopus101 WoS88 Europe PMC91 |
| 2015 |
Al Darwish, R., Staudacher, A., Bezak, E., & Brown, M. (2015). Autoradiography imaging in targeted alpha therapy with Timepix detector. Computational and Mathematical Methods in Medicine, 2015(612580), 612580-1-612580-7.
DOI Scopus15 WoS9 Europe PMC9 |
| 2015 |
Singhal, N., Vatandoust, S., & Brown, M. (2015). Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity. Cancer Chemotherapy and Pharmacology, 75(2), 325-331.
DOI Scopus12 WoS10 Europe PMC7 |
| 2014 |
Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, H., Brown, M., . . . Kefford, R. (2014). Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clinical Cancer Research, 20(17), 4449-4458.
DOI Scopus63 WoS62 Europe PMC52 |
| 2014 |
Gargett, T., & Brown, M. (2014). The inducible caspase-9 suicide gene system as a 'safety switch' to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology, 5(235), 235-1-235-7.
DOI Scopus325 WoS296 Europe PMC280 |
| 2014 |
Eberhardt, W. E. E., Mitchell, P., Schiller, J. H., Brown, M. P., Thomas, M., Mills, G., . . . Papadimitrakopoulou, V. (2014). Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Investigational New Drugs, 32(1), 123-134.
DOI Scopus5 WoS5 Europe PMC4 |
| 2014 |
Al-Ejeh, F., Staudacher, A., Smyth, D., Darby, J., Denoyer, D., Tsopelas, C., . . . Brown, M. (2014). Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 55(5), 772-779.
DOI Scopus16 WoS15 Europe PMC15 |
| 2014 |
Harata-Lee, Y., Turvey, M., Brazzatti, J., Gregor, C., Brown, M., Smyth, M., . . . McColl, S. (2014). The atypical chemokine receptor CCX-CKR regulates metastasis of mammary carcinoma via an effect on EMT. Immunology and Cell Biology, 92(10), 815-824.
DOI Scopus17 WoS18 Europe PMC18 |
| 2014 |
Penfold, S., Brown, M., Staudacher, A., & Bezak, E. (2014). Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy. Applied Radiation and Isotopes, 90, 40-45.
DOI Scopus10 WoS8 Europe PMC7 |
| 2014 |
Staudacher, A., Bezak, E., Borysenko, A., & Brown, M. (2014). Targeted [alpha]-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation. Nuclear Medicine Communications, 35(12), 1284-1290.
DOI Scopus20 WoS20 Europe PMC21 |
| 2014 |
Roder, D., Fong, K., Brown, M., Zalcberg, J., & Wainwright, C. (2014). Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia. European Journal of Cancer Care, 23(6), 721-727.
DOI Scopus20 WoS17 Europe PMC18 |
| 2014 |
Shahnam, A., Roder, D., Tracey, E., Neuhaus, S., Brown, M., & Sorich, M. (2014). Can cancer registries show whether treatment is contributing to survival increases for melanoma of the skin at a population level?. Journal of Evaluation in Clinical Practice, 20(1), 74-80.
DOI Scopus2 WoS2 Europe PMC2 |
| 2014 |
Al-Ejeh, F., Pajic, M., Shi, W., Kalimutho, M., Miranda, M., Nagrial, A., . . . Khanna, K. (2014). Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(12), 3187-3197.
DOI Scopus37 WoS32 Europe PMC27 |
| 2014 |
Brown, M., & Staudacher, A. (2014). Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?. Immunotherapy, 6(4), 371-375.
DOI Scopus14 WoS12 Europe PMC10 |
| 2014 |
Larkin, J., Del Vecchio, M., Ascierto, P., Krajsova, I., Schachter, J., Neyns, B., . . . Blank, C. (2014). Vemurafenib in patients with BRAFv⁶⁰⁰ mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet Oncology, 15(4), 436-444.
DOI Scopus245 WoS215 Europe PMC188 |
| 2014 |
Simovic, S., Diener, K., Bachhuka, A., Kant, K., Losic, D., Hayball, J., . . . Vasilev, K. (2014). Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: a potential in situ therapeutic device. Materials Letters, 130, 210-214.
DOI Scopus11 WoS11 |
| 2014 |
Staudacher, A., Al-ejeh, F., Fraser, C., Darby, J., Roder, D., Ruszkiewicz, A., . . . Brown, M. (2014). The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the la-specific antibody APOMAB®. EJNMMI Research, 4(article no. 2), 2-1-2-13.
DOI Scopus24 WoS21 Europe PMC22 |
| 2014 |
Pishas, K., Neuhaus, S., Clayer, M., Schreiber, A., Lawrence, D., Perugini, M., . . . Neilsen, P. (2014). Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Research, 74(3), 921-931.
DOI Scopus22 WoS22 Europe PMC22 |
| 2014 |
Vatandoust, S., Singhal, N., & Brown, M. P. (2014). PHASE-2 STUDY OF EVEROLIMUS WITH LETROZOLE IN ADVANCED NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PLATINUM-BASED TREATMENT: ANALYSIS OF TOXICITY. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, 66. |
| 2014 |
Brown, M. P., & Long, G. V. (2014). The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation. Asia Pacific Journal of Clinical Oncology, 10(S3), 1-15.
DOI Scopus6 WoS5 Europe PMC4 |
| 2014 |
Gibbs, P., Gebski, V., Van Buskirk, M., Thurston, K., Cade, D. N., Van Hazel, G. A., . . . Tatsch, K. (2014). Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study. BMC Cancer, 14(1), 10 pages.
DOI Scopus55 WoS48 Europe PMC38 |
| 2014 |
Rady, K., Walters, G., Brown, M., & Talaulikar, G. (2014). Allograft adenovirus nephritis. Clinical Kidney Journal, 7(3), 289-292.
DOI Scopus16 |
| 2013 |
Jennings, S., Tharion, J., Jones, P., & Brown, M. (2013). Bronchial Haemangioma: Exceptionally Rare Cause of Haemoptysis. Heart Lung and Circulation, 22(12), 1030-1032.
DOI Scopus3 Europe PMC3 |
| 2013 |
Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., . . . Long, G. (2013). Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clinical Cancer Research, 19(17), 4868-4878.
DOI Scopus156 WoS143 Europe PMC144 |
| 2013 |
Stevens, N., Fraser, C., Alsharifi, M., Brown, M., Diener, K., & Hayball, J. (2013). An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant. PLoS One, 8(7), 1-10.
DOI Scopus11 WoS9 Europe PMC10 |
| 2013 |
Brown, M., & Burdett, N. (2013). Targeted therapies, aspects of pharmaceutical and oncological management. Cancer Forum, 37(1), 70-80.
Scopus4 WoS3 |
| 2013 |
Al-ejeh, F., Shi, W., Miranda, M., Simpson, P., Vargas, A., Song, S., . . . Khanna, K. (2013). Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of Nuclear Medicine, 54(6), 913-921.
DOI Scopus66 WoS56 Europe PMC47 |
| 2013 |
Pishas, K., Neuhaus, S., Clayer, M., Adwal, A., Brown, M., Evdokiou, A., . . . Neilsen, P. (2013). Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy. Oncology Reports, 30(1), 471-477.
DOI Scopus4 WoS5 Europe PMC2 |
| 2013 |
Mellor, J., Brown, M., Irving, H., Zalcberg, J., & Dobrovic, A. (2013). A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. Journal of Hematology & Oncology, 6(1), 1-10.
DOI Scopus254 WoS239 Europe PMC245 |
| 2012 |
Barrios, C., Hernandez-Barajas, D., Brown, M., Lee, S., Fein, L., Liu, J., . . . Rha, S. (2012). Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer, 118(5), 1252-1259.
DOI Scopus80 WoS77 Europe PMC77 |
| 2012 |
Miller, D., Brown, M., Howley, P., & Hayball, J. (2012). Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy. Expert Review of Vaccines, 11(12), 1471-1481.
DOI Scopus7 WoS7 Europe PMC5 |
| 2012 |
Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, T., Brown, M., . . . Kefford, R. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, 379(9829), 1893-1901.
DOI Scopus847 WoS773 Europe PMC686 |
| 2012 |
Christo, S., Sarvestani, G., Griesser, S., Coad, B., Griesser, H., Vasilev, K., . . . Hayball, J. (2012). Individual and population quantitative analyses of calcium flux in T-cells activated on functionalized material surfaces. Australian Journal of Chemistry, 65(1), 45-49.
DOI Scopus7 WoS7 |
| 2012 |
Brown, M. P. (2012). Is the induction of tumor cell senescence the key to a good irradiated tumor vaccine?. Molecular Therapy, 20(5), 884-886.
DOI |
| 2012 |
Sharma, A., Tan, T. H., Cheetham, G., Scott, H. S., & Brown, M. P. (2012). Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases. Journal of Thoracic Oncology, 7(5), 941-942.
DOI Scopus14 WoS11 Europe PMC7 |
| 2012 |
Reinbrecht, S., Zwart, E., Robinson, P., & Brown, M. (2012). The new model of lung cancer care is multidisciplinary: the South Australian experience of pathway development. Journal of Thoracic Oncology, 7(9), S181. |
| 2011 |
Bishnoi, S., Pittman, K., Yeend, S., Brown, M., Koczwara, B., Kotasek, D., . . . Price, T. (2011). Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: Analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study. Journal of Geriatric Oncology, 2(4), 233-238.
DOI Scopus1 WoS1 |
| 2011 |
Lousberg, E., Diener, K., Brown, M., & Hayball, J. (2011). Innate immune recognition of poxviral vaccine vectors. Expert Review of Vaccines, 10(10), 1435-1449.
DOI Scopus16 WoS16 Europe PMC15 |
| 2011 |
Kurkuri, M., Al-ejeh, F., Shi, J., Palms, D., Prestidge, C., Griesser, H., . . . Thierry, B. (2011). Plasma functionalized PDMS microfluidic chips: towards point-of-care capture of circulating tumor cells. Journal of Materials Chemistry, 21(24), 8841-8848.
DOI Scopus36 WoS34 |
| 2011 |
Al-ejeh, F., Smart, C., Morrison, B., Chenevix-Trench, G., Lopez, J., Lakhani, S., . . . Khanna, K. (2011). Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis, 32(5), 650-658.
DOI Scopus118 WoS102 Europe PMC93 |
| 2011 |
Lousberg, E., Diener, K., Fraser, C., Phipps, S., Foster, P., Chen, W., . . . Hayball, J. (2011). Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition. Journal of Virology, 85(7), 3385-3396.
DOI Scopus12 WoS11 Europe PMC13 |
| 2011 |
Pishas, K., Al-ejeh, F., Zinonos, I., Kumar, R., Evdokiou, A., Brown, M., . . . Neilsen, P. (2011). Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clinical Cancer Research, 17(3), 494-504.
DOI Scopus61 WoS61 Europe PMC55 |
| 2011 |
Kirkwood, J. M., Gonzalex, R., Reintgen, D., Clingan, P. R., McWilliams, R. R., de Alwis, D. P., . . . Millward, M. J. (2011). A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer, 117(20), 4732-4739.
DOI Scopus22 WoS21 Europe PMC22 |
| 2011 |
Brown, M. P. (2011). Do human lymphocyte antigens play a role in the clinical antimelanoma activity of ipilimumab?. Immunotherapy, 3(5), 595-599.
DOI Scopus2 WoS2 Europe PMC1 |
| 2011 |
Subramaniam, K., Chitturi, S., Brown, M., & Pavli, P. (2011). Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate. Inflammatory Bowel Diseases, 17(11), E149-E150.
DOI Scopus28 Europe PMC24 |
| 2010 |
Karthaus, M., Karapetis, C. S., Brown, M. P., Pavlakis, N., Trarbach, T., Marschner, N., . . . Luigi, M. (2010). A randomized, double-blind, placebo-controlled trial for prevention of oxalipatin-induced peripheral neuropathy symptoms with pregabalin in patients with advanced colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
DOI WoS1 |
| 2010 |
Thierry, B., Barbe, C., Al-Ejeh, F., Brown, M., & Griesser, H. J. (2010). PEGylated nanoparticles for cancer detection and treatment. European Cells and Materials, 20(SUPPL.3), 95. |
| 2010 |
Yew, C. T., Talaulikar, G. S., Falk, M. C., Clayton, P., DRozario, J., & Brown, M. (2010). Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology, 15(3), 377.
DOI Scopus18 WoS13 Europe PMC12 |
| 2010 |
Fraser, C., Lousberg, E., Guerin, L., Hughes, T., Brown, M., Diener, K., & Hayball, J. (2010). Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biology & Therapy, 10(7), 715-727.
DOI Scopus11 WoS11 Europe PMC9 |
| 2010 |
Fraser, C., Diener, K., Lousberg, E., Both, G., Ward, L., Brown, M., & Hayball, J. (2010). Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus. Clinical and Vaccine Immunology, 17(11), 1679-1686.
DOI Scopus6 WoS5 Europe PMC4 |
| 2010 |
Al-ejeh, F., Sharma, R., Wiegmans, A., Lakhani, S., Brown, M., & Khanna, K. (2010). Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene, 29(46), 6085-6098.
DOI Scopus119 WoS115 Europe PMC103 |
| 2010 |
Fraser, C., Brown, M., Diener, K., & Hayball, J. (2010). Unravelling the complexity of cancer-immune system interplay. Expert Review of Anticancer Therapy, 10(6), 917-934.
DOI Scopus5 WoS5 Europe PMC3 |
| 2009 |
Al-ejeh, F., Darby, J., & Brown, M. (2009). Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One, 4(2), 1-13.
DOI Scopus31 WoS28 Europe PMC26 |
| 2009 |
Al-ejeh, F., Darby, J., Tsopelas, C., Smyth, D., Manavis, J., & Brown, M. (2009). APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy. PLoS One, 4(2), 1-11.
DOI Scopus33 WoS30 Europe PMC29 |
| 2009 |
Moldenhauer, L., Diener, K., Thring, D., Brown, M., Hayball, J., & Robertson, S. (2009). Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy. Journal of Immunology, 182(12), 8080-8093.
DOI Scopus221 WoS205 Europe PMC190 |
| 2009 |
Al-ejeh, F., Darby, J., Thierry, B., & Brown, M. (2009). A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution. Nuclear Medicine and Biology, 36(4), 395-402.
DOI Scopus39 WoS38 Europe PMC35 |
| 2009 |
Diener, K., Woods, A., Manavis, J., Brown, M., & Hayball, J. (2009). Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Laboratory Investigation, 89(2), 142-151.
DOI Scopus14 WoS14 Europe PMC13 |
| 2009 |
Fraser, C., Blake, S., Diener, K., Lyons, A., Brown, M., Hughes, T., & Hayball, J. (2009). Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology, 37(2), 256-265.
DOI Scopus58 WoS56 Europe PMC51 |
| 2009 |
Thierry, B., Al-Ejeh, F., Brown, M., Majewski, P., & Griesser, H. (2009). Immunotargeting of functional nanoparticles for MRI detection of apoptotic tumor cells. Advanced Materials, 21(5), 541-545.
DOI Scopus33 WoS28 Europe PMC19 |
| 2009 |
Smyth, D., Al-Ejeh, F., Tsopelas, C., Brown, M., & Chatterton, B. (2009). Molecular imaging with gallium-68 labelled biomolecules. ANZ Nuclear Medicine, 40(2), 1.
Scopus1 |
| 2009 |
Thierry, B., Al Ejeh, F., Khatri, A., Yuan, Z., Russell, P. J., Ping, S., . . . Majewski, P. (2009). Multifunctional core-shell magnetic cisplatin nanocarriers. Chemical communications, 2009(47), 7348-7350.
DOI Scopus29 WoS30 Europe PMC15 |
| 2008 |
Luke, C., Koczwara, B., Karapetis, C., Pittman, K., Price, T., Kotasek, D., . . . Roder, D. (2008). Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Australian and New Zealand Journal of Public Health, 32(4), 383-389.
DOI Scopus30 WoS31 Europe PMC26 |
| 2008 |
Diener, K., Lousberg, E., Beukema, E., Yu, A., Howley, P., Brown, M., & Hayball, J. (2008). Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help. Vaccine, 26(29-30), 3566-3573.
DOI Scopus10 WoS7 Europe PMC7 |
| 2008 |
Diener, K., Moldenhauer, L., Lyons, A., Brown, M., & Hayball, J. (2008). Human Flt-3 ligand-mobilized dendritic cells, require additional activation to drive effective immune responses. Experimental Hematology, 36(1), 51-60.
DOI Scopus18 WoS18 Europe PMC16 |
| 2008 |
Philpott, H., Hissaria, P., Warren, L., Singhal, N., Brown, M., Proudman, S., . . . Gillis, D. (2008). Eosinophilic fasciitis as a paraneoplastic phenomenon associated with metastatic colorectal carcinoma. Australasian Journal of Dermatology, 49(1), 27-29.
DOI Scopus20 WoS16 Europe PMC10 |
| 2008 |
Fock, K., Talley, N., Fass, R., Goh, K., Katelaris, P., Hunt, R., . . . Manatsathit, S. (2008). Asia-Pacific consensus on the management of gastroesophageal reflux disease: Update. Journal of Gastroenterology and Hepatology, 23(1), 8-22.
DOI Scopus159 WoS137 Europe PMC120 |
| 2008 |
Talaulikar, D., Choudhury, A., Shadbolt, B., & Brown, M. (2008). Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leukemia and Lymphoma, 49(5), 959-964.
DOI Scopus35 Europe PMC27 |
| 2007 |
Ramalingam, S. S., Parise, R. A., & Ramanathan, R. K. (2007). Clinical cancer research (vol 13, pg 3605, 2007). CLINICAL CANCER RESEARCH, 13(20), 6245.
DOI WoS1 |
| 2007 |
Fraser, C., Diener, K., Brown, M., & Hayball, J. (2007). Improving vaccines by incorporating immunological coadjuvants. Expert Review of Vaccines, 6(4), 559-578.
DOI Scopus80 WoS68 Europe PMC54 |
| 2007 |
Brown, M., Wilkinson, C., Rudzi, Z., & Olver, I. (2007). Why we will need to learn new skills to control cancer. Internal Medicine Journal, 37(3), 201-204.
DOI Scopus4 WoS4 Europe PMC2 |
| 2007 |
Al-ejeh, F., Darby, J., Pensa, K., Diener, K., Hayball, J., & Boucaut, R. (2007). In vivo targeting of dead tumor cells in a Murine Tumor Model using a monoclonal antibody specific for the La Autoantigen. Clinical Cancer Research, 13(18), 5519-5527.
DOI Scopus33 WoS27 Europe PMC26 |
| 2007 |
Al-Ejeh, F., Darby, J. M., & Brown, M. P. (2007). The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs. Clinical Cancer Research, 13(18), 5509S-5518S.
DOI Scopus39 WoS35 Europe PMC34 |
| 2007 |
Singhal, N., Selva-Nayagam, S., & Brown, M. P. (2007). Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. Journal of Neuro Oncology, 85(2), 229-230.
DOI Scopus37 WoS29 Europe PMC31 |
| 2007 |
Fraser, C. K., Diener, K. R., Brown, M. P., & Hayball, J. D. (2007). Erratum: Improving vaccines by incorporating immunological coadjuvants (Expert Review Vaccines (2007) 6, 4, (559-578)). Expert Review of Vaccines, 6(6), 1022.
DOI |
| 2007 |
Fares, A. E., Darby, J. M., Pensa, K., Diener, K. R., Haybal, J. D., & Brown, M. P. (2007). Erratum: Article on la Autoantigen (Clinical Cancer Research (2007) 13, (5519s-5527s)). Clinical Cancer Research, 13(20), 645.
DOI |
| 2006 |
Rousseau, R. F., Biagi, E., Dutour, A., Yvon, E. S., Brown, M. P., Lin, T., . . . Brenner, M. K. (2006). Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood, 107(4), 1332-1341.
DOI Scopus60 WoS51 Europe PMC42 |
| 2006 |
Thierry, B., Al Ejeh, F., Majewsky, P., Griesser, H., & Brown, M. P. (2006). Immunotargeting of advanced functional nanostructures for cancer diagnosis and treatment. Cancer Biotherapy and Radiopharmaceuticals, 21(4), 385. |
| 2006 |
Beukema, E., Brown, M., & Hayball, J. (2006). The potential role of fowlpox virus in rational vaccine design. Expert Review of Vaccines, 5(4), 565-577.
DOI Scopus24 WoS21 Europe PMC19 |
| 2006 |
Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024.
DOI Scopus15 WoS14 Europe PMC14 |
| 2006 |
Lees, J., Charbonneau, B., Hayball, J., Diener, K., Brown, M., Matusik, R., . . . Ratliff, T. (2006). T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate, 66(6), 578-590.
DOI Scopus26 WoS25 Europe PMC25 |
| 2003 |
Zhang, L., Brereton, H., Hahn, M., Froscio, M., Tilley, W., Brown, M., & Barritt, G. (2003). Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Therapy, 10(8), 611-625.
DOI Scopus9 WoS7 Europe PMC8 |
| 2003 |
Harcourt, J., Brown, M., Anderson, L., & Tripp, R. (2003). CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine, 21(21-22), 2964-2979.
DOI Scopus27 WoS24 Europe PMC23 |
| 2003 |
Krance, R., Kuehnle, I., Rill, D., Mei, Z., Pinetta, C., Evans, W., . . . Brenner, M. (2003). Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biology of Blood and Marrow Transplantation, 9(4), 273-281.
DOI Scopus24 WoS23 Europe PMC21 |
| 2003 |
Brenner, M., Wulf, G., Rill, D., Luo, K., Mei, M., Kuehnle, I., . . . Krance, R. (2003). Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Annals of the New York Academy of Sciences, 996(1), 80-88.
DOI Scopus19 WoS18 Europe PMC14 |
| 2003 |
Verweij, J., Van Oosterom, A., Blay, J. Y., Judson, I., Rodenhuis, S., Van Der Graaf, W., . . . Nielsen, O. S. (2003). Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. European Journal of Cancer, 39(14), 2006-2011.
DOI Scopus412 Europe PMC213 |
| 2002 |
Moghaddami, M., Swart, B., Reynolds, P., Diener, K., & Brown, M. (2002). Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate. Immunology and Cell Biology, 80(4), 370-381.
DOI Scopus7 WoS8 Europe PMC6 |
| 2002 |
Olver, I., Hercus, T., Lopez, A., Vadas, M., Somogyi, A., Doyle, I., . . . Wigley, P. (2002). A phase I study of the GM-CSF antagonist E21R. Cancer Chemotherapy and Pharmacology, 50(3), 171-178.
DOI Scopus8 WoS8 Europe PMC7 |
| 2002 |
Moghaddami, M., Swart, B., Reynolds, P., Diener, K., & Brown, M. P. (2002). Erratum: Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate (Immunology and Cell Biology (2002) 80 (370-381)). Immunology and Cell Biology, 80(5), 507.
DOI |
| 2001 |
Loskog, A., Björkland, A., Brown, M. P., Korsgren, O., Malmström, P. U., & Tötterman, T. H. (2001). Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. Journal of Urology, 166(3), 1093-1097.
DOI Scopus38 WoS35 Europe PMC31 |
| 2001 |
Dotti, G., Savoldo, B., Takahashi, S., Goltsova, T., Brown, M., Rill, D., . . . Brenner, M. (2001). Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: A model for immunotherapy. Experimental Hematology, 29(8), 952-961.
DOI Scopus36 WoS35 Europe PMC33 |
| 2001 |
Healey, T., & Brown, M. (2001). Febrile neutropenia - An oncological emergency. Current Therapeutics, 42(10), 41-45.
Scopus1 |
| 2001 |
Moghaddami, M., Cohen, P., Stapleton, A., & Brown, M. (2001). CD40 is not detected on human prostate cancer cells by immunohistologic techniques. Urology, 57(3), 573-578.
DOI Scopus7 WoS7 Europe PMC4 |
| 2000 |
Pincombe, J., Brown, M., Thorne, D., Ballantyne, A., & McCutcheon, H. (2000). Care of Dying Patients in the Acute Hospital. Progress in Palliative Care, 8(2), 71-77.
DOI |
| 2000 |
Sexl, V., Piekorz, R., Moriggl, R., Rohrer, J., Brown, M. P., Bunting, K. D., . . . Ihle, J. N. (2000). Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. Blood, 96(6), 2277-2283.
DOI Scopus178 WoS171 Europe PMC102 |
| 2000 |
Tripp, R. A., Jones, L., Anderson, L. J., & Brown, M. P. (2000). CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. Journal of Immunology, 164(11), 5913-5921.
DOI Scopus59 WoS50 Europe PMC36 |
| 1999 |
Brown, M., Nosaka, T., Tripp, R., Brooks, J., van Deursen, J., Brenner, M., . . . Ihle, J. (1999). Reconstitution of Early Lymphoid Proliferation and Immune Function in Jak3-Deficient Mice by Interleukin-3. Blood, 94(6), 1906-1914.
DOI Scopus30 WoS27 Europe PMC15 |
| 1999 |
Brown, M. (1999). Cytokines, Jaks, Stats, health and disease. Australian and New Zealand Journal of Medicine, 29(-), 73-78.
DOI |
| 1998 |
Bowman, L., Grossmann, M., Rill, D., Brown, M., Zhong, W. Y., Alexander, B., . . . Brenner, M. (1998). IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood, 92(6), 1941-1949.
DOI Scopus117 WoS96 Europe PMC72 |
| 1998 |
Bowman, L. C., Grossmann, M., Rill, D., Brown, M., Zhong, W. Y., Alexander, B., . . . Brenner, M. (1998). Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Human Gene Therapy, 9(9), 1303-1311.
DOI Scopus82 WoS66 Europe PMC53 |
| 1998 |
Brown, M. P., Topham, D. J., Sangster, M. Y., Zhao, J., Flynn, K. J., Surman, S. L., . . . Brenner, M. K. (1998). Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nature Medicine, 4(11), 1253-1260.
DOI Scopus136 WoS116 Europe PMC104 |
| 1998 |
Okubo, M., Brown, M. P., Chiba, K., Kasukawa, R., & Nishimaki, T. (1998). Detection of TNF α and Fas ligand mRNA within synovial mononuclear cells by fluorescence in-cell labeling PCR (FICL-PCR). Molecular Biology Reports, 25(4), 217-224.
DOI Scopus8 WoS8 Europe PMC3 |
| 1998 |
Teglund, S., McKay, C., Schuetz, E., Van Deursen, J. M., Stravopodis, D., Wang, D., . . . Ihle, J. N. (1998). Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell, 93(5), 841-850.
DOI Scopus1111 WoS1065 Europe PMC880 |
| 1998 |
Dilloo, D., Brown, M., Zhong, W., & Brenner, M. (1998). CD40 ligand as a co-stimulator molecule for the generation of an antitumor response. Medical and Pediatric Oncology, 30(2), 138. |
| 1998 |
Zardawi, I. M., Bennett, G., Jain, S., & Brown, M. (1998). The role of peer review in internal quality assurance in cytopathology. Pathology, 30(3), 309-313.
DOI Scopus5 Europe PMC3 |
| 1998 |
Zardawi, I. M., Bennett, G., Jain, S., & Brown, M. (1998). Internal quality assurance activities of a surgical pathology department in an Australian teaching hospital. Journal of Clinical Pathology, 51(9), 695-699.
DOI Scopus28 Europe PMC8 |
| 1997 |
Grossmann, M. E., Brown, M. P., & Brenner, M. K. (1997). Antitumor responses induced by transgenic expression of CD40 ligand. Human Gene Therapy, 8(16), 1935-1943.
DOI Scopus64 WoS63 Europe PMC47 |
| 1997 |
Dilloo, D., Brown, M., Roskrow, M., Zhong, W., Holladay, M., Holden, W., & Brenner, M. (1997). CD40 ligand induces an antileukemia immune response in vivo. Blood, 90(5), 1927-1933.
DOI Scopus122 WoS118 Europe PMC62 |
| 1989 |
Pui, C. H., Ip, S. H., Thompson, E., Dodge, R. K., Brown, M., Wilimas, J., . . . Crist, W. M. (1989). Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood, 73(1), 209-213.
DOI Scopus43 Europe PMC26 |
| 1989 |
Pui, C. H., Ip, S. H., Thompson, E., Wilimas, J., Brown, M., Dodge, R. K., . . . Crist, W. M. (1989). High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease. Leukemia, 3(7), 481-484.
Scopus40 Europe PMC23 |
| 1988 |
Pui, C. H., Ip, S. H., Dodge, R. K., Carrabis, S., Brown, M., Crist, W. M., . . . Murphy, S. B. (1988). Serum levels of CD8 antigen in childhood lymphoid malignancies: A possible indicator of increased suppressor cell activity in poor-risk patients. Blood, 72(3), 1015-1021.
DOI Scopus45 Europe PMC24 |
